Skip to content

Clinical trials

Phase 4 Diabetes Mellitus, Type 2 trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 2 Phase: Phase 4 Country / region: United States Clear all

294 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20017
20026
200312
200411
20058
200616
200713
200817
200919
201014
20118
20128
201316
201422
201517
201615
20177
201812
201915
20205
20219
20228
20237
20248
20255
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed207
Terminated41
Withdrawn13
Recruiting12
Unknown status9
Active, not recruiting7
Suspended2
Enrolling by invitation2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S17
Emory University15
Eli Lilly and Company14
Sanofi13
The University of Texas Health Science Center at San Antonio12
GlaxoSmithKline11
AstraZeneca9
University of Florida7
Baylor College of Medicine6
University of Texas Southwestern Medical Center6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 2294
Diabetes Mellitus78
Insulin Resistance27
Obesity22
Hypertension18
Hyperglycemia14
Diabetes Mellitus, Type 113
Inflammation8
Coronary Artery Disease7
Overweight7

Trials

Showing 1 to 25 of 294. Each trial links to its page on Pharma Observatory.

194 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.